Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson’s disease

Bibliography

• de Rijk MC, Launer LJ, Berger K, et al. Prevalence of Parkinson’s disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54(11 Suppl 5):S21-3
   PubMed Web of Science ®Google Scholar
• Rajput AH, Birdi S. Epidemiology of Parkinson’s disease. Parkinsonism Relat Disord 1997;3(4):175-86
   PubMedGoogle Scholar
• Przuntek H, Müller T, Riederer P. Diagnostic staging of Parkinson’s disease: conceptual aspects. J Neural Transm 2004;111(2):201-16
   PubMed Web of Science ®Google Scholar
• Brotchie J, Fitzer-Attas C. Mechanisms compensating for dopamine loss in early Parkinson disease. Neurology 2009;72(Suppl 7):S32-8
   PubMedGoogle Scholar
• Clarke CE, Patel S, Ives N, et al. Should treatment for Parkinson’s disease start immediately on diagnosis or delayed until functional disability develops? Mov Disord 2011;26(7):1187-93
   PubMed Web of Science ®Google Scholar
• Müller T, Pietsch A. Comparison of gait training versus cranial osteopathy in patients with Parkinson’s disease: a pilot study. NeuroRehabilitation 2013;32(1):135-40
   PubMed Web of Science ®Google Scholar
• Tomlinson CL, Patel S, Meek C, et al. Physiotherapy versus placebo or no intervention in Parkinson’s disease [abstract]. Cochrane Database Syst Rev 2013;9:CD002817
   PubMed Web of Science ®Google Scholar
• van Nimwegen M, Speelman AD, Overeem S, et al. Promotion of physical activity and fitness in sedentary patients with Parkinson’s disease: randomised controlled trial. BMJ 2013;346:576-81
   PubMed Web of Science ®Google Scholar
• Foster ER, Golden L, Duncan RP, Earhart GM. Community-based Argentine tango dance program is associated with increased activity participation among individuals with Parkinson’s disease. Arch Phys Med Rehabil 2013;94(2):240-9
   PubMed Web of Science ®Google Scholar
• Gao Q, Leung A, Yang Y, et al. Effects of Tai Chi on balance and fall prevention in Parkinson’s disease: a randomized controlled trial. Clin Rehabil 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Müller T, Muhlack S. Effect of exercise on reactivity and motor behaviour in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 2010;81(7):747-53
   PubMed Web of Science ®Google Scholar
• Müller T. Drug therapy in patients with Parkinson’s disease. Transl Neurodegener 2012;1(1):10
   Google Scholar
• Birkmayer W, Hornykiewicz O. The effect of l-3,4-dihydroxyphenylalanine (= DOPA) on akinesia in parkinsonism. 1961. Wien Klin Wochenschr 2001;113(22):851-4
   PubMed Web of Science ®Google Scholar
• Hubsher G, Haider M, Okun MS. Amantadine: the journey from fighting flu to treating Parkinson disease. Neurology 2012;78(14):1096-9
   PubMed Web of Science ®Google Scholar
• Eggert K, Larisch A, Dodel R, et al. Awareness and knowledge of the clinical practice guideline on Parkinson’s disease among German neurologists. Eur Neurol 2009;61(4):216-22
   PubMed Web of Science ®Google Scholar
• Ehret R, Balzer-Geldsetzer M, Reese JP, et al. [Direct costs for Parkinson’s treatment in private neurology practices in Berlin]. Nervenarzt 2009;80(4):452-8
   PubMed Web of Science ®Google Scholar
• Larisch A, Reuss A, Oertel WH, Eggert K. Does the clinical practice guideline on Parkinson’s disease change health outcomes? A cluster randomized controlled trial. J Neurol 2011;258(5):826-34
   PubMed Web of Science ®Google Scholar
• Möller JC, Körner Y, Dodel RC, et al. Pharmacotherapy of Parkinson’s disease in Germany. J Neurol 2005;252(8):926-35
   PubMed Web of Science ®Google Scholar
• Schröder S, Kuessner D, Arnold G, et al. Do neurologists in Germany adhere to the national Parkinson’s disease guideline? Neuropsychiatr Dis Treat 2011;7:103-10
   PubMed Web of Science ®Google Scholar
• Kovacs N, Janszky J, Nagy F. Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson’s disease in the UK setting: an economic Markov model evaluation. Drugs Aging 2011;28(2):161-2
   PubMed Web of Science ®Google Scholar
• Schuepbach WM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson’s disease with early motor complications. N Engl J Med 2013;368(7):610-22
   PubMed Web of Science ®Google Scholar
• Kirsch-Darrow L, Mikos A, Bowers D. Does deep brain stimulation induce apathy in Parkinson’s disease? Front Biosci 2008;13:5316-22
   PubMed Web of Science ®Google Scholar
• Smeding HM, Speelman JD, Huizenga HM, et al. Predictors of cognitive and psychosocial outcome after STN DBS in Parkinson’s Disease. J Neurol Neurosurg Psychiatry 2011;82(7):754-60
   PubMed Web of Science ®Google Scholar
• Witt K, Daniels C, Reiff J, et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson’s disease: a randomised, multicentre study. Lancet Neurol 2008;7(7):605-14
   PubMed Web of Science ®Google Scholar
• Romito LM, Albanese A. Dopaminergic therapy and subthalamic stimulation in Parkinson’s disease: a review of 5-year reports. J Neurol 2010;257(Suppl 2):S298-304
   PubMedGoogle Scholar
• Zibetti M, Cinquepalmi A, Angrisano S, et al. Management of antiparkinsonian therapy during chronic subthalamic stimulation in Parkinson’s disease. Parkinsonism Relat Disord 2009;15(Suppl 4):S76-80
   PubMedGoogle Scholar
• Hassan A, Wu SS, Schmidt P, et al. What are the issues facing Parkinson’s disease patients at ten years of disease and beyond? Data from the NPF-QII study. Parkinsonism Relat Disord 2012;18(Suppl 3):S10-14
   PubMedGoogle Scholar
• Oyama G, Okun MS, Schmidt P, et al. Deep brain stimulation may improve quality of life in people with Parkinson’s disease without affecting caregiver burden. Neuromodulation 2014;17(2):126-32
   PubMed Web of Science ®Google Scholar
• Soileau MJ, Persad C, Taylor J, et al. Caregiver burden in patients with Parkinson disease undergoing deep brain stimulation: an exploratory analysis. J Parkinsons Dis 2014. [Epub ahead of print]
   Google Scholar
• Hauser R, Stocchi F, Rascol O, et al. Phase-3 clinical trials of adjunctive therapy with preladenant, an adenosine 2a antagonist, in patients with Parkinson’s disease [abstract]. Neurology 2014;82(Suppl 10):P7.087
   Google Scholar
• Goetz CG, Damier P, Hicking C, et al. Sarizotan as a treatment for dyskinesias in Parkinson’s disease: a double-blind placebo-controlled trial. Mov Disord 2007;22(2):179-86
   PubMed Web of Science ®Google Scholar
• Goetz CG, Laska E, Hicking C, et al. Placebo influences on dyskinesia in Parkinson’s disease. Mov Disord 2008;23(5):700-7
   PubMed Web of Science ®Google Scholar
• Rascol O, Fox S, Gasparini F, et al. Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias. Parkinsonism Relat Disord 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Pilleri M, Antonini A. Novel levodopa formulations in the treatment of Parkinson’s disease. Expert Rev Neurother 2014;14(2):143-9
   PubMed Web of Science ®Google Scholar
• Muhlack S, Herrmann L, Salmen S, Müller T. Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition. J Neural Transm 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Ngwuluka N, Pillay V, Du Toit LC, et al. Levodopa delivery systems: advancements in delivery of the gold standard. Expert Opin Drug Deliv 2010;7(2):203-24
   PubMed Web of Science ®Google Scholar
• Garcia-Ruiz PJ, Martinez Castrillo JC, Alonso-Canovas A, et al. Impulse control disorder in patients with Parkinson’s disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Perez-Lloret S, Rey MV, Crispo J, et al. Risk of heart failure following treatment with dopamine agonists in Parkinson’s disease patients. Expert Opin Drug Saf 2014;13(3):351-60
   PubMed Web of Science ®Google Scholar
• Müller T, Hoffmann JA, Dimpfel W, Oehlwein C. Switch from selegiline to rasagiline is beneficial in patients with Parkinson’s disease. J Neural Transm 2013;120(5):761-5
   PubMed Web of Science ®Google Scholar
• Dimpfel W, Hoffmann JA. Effects of rasagiline, its metabolite aminoindan and selegiline on glutamate receptor mediated signalling in the rat hippocampus slice in vitro. BMC Pharmacol 2011;11:2-7
   PubMedGoogle Scholar
• Müller T. Current status of safinamide for the drug portfolio of Parkinson’s disease therapy. Expert Rev Neurother 2013;13(9):969-77
   PubMed Web of Science ®Google Scholar
• Bartl J, Müller T, Grunblatt E, et al. Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity. J Neural Transm 2014;121(4):379-83
   PubMed Web of Science ®Google Scholar
• Riederer P, Laux G. MAO-inhibitors in Parkinson’s Disease. Exp Neurobiol 2011;20(1):1-17
   PubMedGoogle Scholar
• Teo KC, Ho SL. Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson’s disease. Transl Neurodegener 2013;2(1):19-27
   Google Scholar
• Rascol O. Rasagiline in the pharmacotherapy of Parkinson’s disease–a review. Expert Opin Pharmacother 2005;6(12):2061-75
   PubMed Web of Science ®Google Scholar
• Hoy SM, Keating GM. Rasagiline: a review of its use in the treatment of idiopathic Parkinson’s disease. Drugs 2012;72(5):643-69
   PubMed Web of Science ®Google Scholar
• Fahn S, McCall WV, Hammon J, et al. The effect of high dose orally disintegrated tablet selegiline, a selective monoaminoxidase B inhibitor, on monoaminoxidase A, and compared to EMSAM (transdermal formulation of selegiline). Neurology 2011;1(Suppl 4):275
   Google Scholar
• Bar-Am O, Yogev-Falach M, Amit T, et al. Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo. J Neurochem 2004;89(5):1119-25
   PubMed Web of Science ®Google Scholar
• Bar-Am O, Weinreb O, Amit T, Youdim MB. Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J 2005;19(13):1899-901
   PubMed Web of Science ®Google Scholar
• Bar-Am O, Amit T, Youdim MB. Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro. J Neurochem 2007;103(2):500-8
   PubMed Web of Science ®Google Scholar
• Bar-Am O, Weinreb O, Amit T, Youdim MB. The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline. J Neurochem 2010;112(5):1131-7
   PubMed Web of Science ®Google Scholar
• Naoi M, Maruyama W, Inaba-Hasegawa K. Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms. Expert Rev Neurother 2013;13(6):671-84
   PubMed Web of Science ®Google Scholar
• Naoi M, Maruyama W, Yi H. Rasagiline prevents apoptosis induced by PK11195, a ligand of the outer membrane translocator protein (18 kDa), in SH-SY5Y cells through suppression of cytochrome c release from mitochondria. J Neural Transm 2013;120(11):1539-51
   PubMed Web of Science ®Google Scholar
• Jenner P, Langston JW. Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline. Mov Disord 2011;26(13):2316-23
   PubMed Web of Science ®Google Scholar
• Lewitt PA. A perspective on adjunctive therapy for Parkinson disease with monoamine oxidase-B inhibition. Clin Neuropharmacol 2007;30(5):305-7
   PubMed Web of Science ®Google Scholar
• Brotchie J, Johnston TH, Visanji NP. 1-Aminoindan, a main metabolite of rasagiline, enhances dopamine release and provides symptomatic benefit in an animal model of Parkinson’s disease. Parkinsonism Relat Disord 2007;13(Suppl 2):102
   Google Scholar
• Chen JJ, Swope DM. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. J Clin Pharmacol 2005;45(8):878-94
   PubMed Web of Science ®Google Scholar
• Chen JJ, Swope DM, Dashtipour K. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson’s disease. Clin Ther 2007;29(9):1825-49
   PubMed Web of Science ®Google Scholar
• Burke WJ. MAO-B inhibitor know-how: back to the pharm. Neurology 2009;73(23):2048
   PubMed Web of Science ®Google Scholar
• Müller T. Detoxification and antioxidative therapy for levodopa-induced neurodegeneration in Parkinson’s disease. Expert Rev Neurother 2013;13(6):707-18
   PubMed Web of Science ®Google Scholar
• Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med 2009;361(13):1268-78
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002;59(12):1937-43
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004;61(4):561-6
   PubMed Web of Science ®Google Scholar
• Rabey JM, Sagi I, Huberman M, et al. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson’s disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol 2000;23(6):324-30
   PubMed Web of Science ®Google Scholar
• Elmer LW. Rasagiline adjunct therapy in patients with Parkinson’s disease: post hoc analyses of the PRESTO and LARGO trials. Parkinsonism Relat Disord 2013;19(11):930-6
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005;62(2):241-8
   PubMed Web of Science ®Google Scholar
• Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005;365(9463):947-54
   PubMed Web of Science ®Google Scholar
• Barone P, Fernandez HH, Ferreira J, et al. Safinamide as an add-on therapy to a stable dose of a single dopamine agonist: results from a randomized, placebo-controlled, 24-week multicenter trial in early idiopathic parkinson disease (PD) patients (MOTION Study). Neurology 2013;80:Meeting Abstracts 1
   PubMed Web of Science ®Google Scholar
• Hauser RA, Silver D, Choudry A, Isaacson S. A placebo controlled, randomized, double-blind study to assess the safety and clinical benefit of rasagiline as an add-on therapy to dopamine agonist monotherapy in early Parkinson’s disease (PD): the ANDANTE study. Neurology 2013;80:Meeting Abstracts 1
   Google Scholar
• Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med 2009;361(13):1268-78
   PubMed Web of Science ®Google Scholar
• Ahlskog JE, Uitti RJ. Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction? Neurology 2010;74(14):1143-8
   PubMed Web of Science ®Google Scholar
• Rascol O, Fitzer-Attas CJ, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol 2011;10(5):415-23
   PubMed Web of Science ®Google Scholar
• Rascol O, Fitzer-Attas CJ, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol 2011;10(5):415-23
   PubMed Web of Science ®Google Scholar
• Lew MF. Rasagiline treatment effects on parkinsonian tremor. Int J Neurosci 2013;123(12):859-65
   PubMed Web of Science ®Google Scholar
• Stocchi F. The concept of continuous dopaminergic stimulation: what we should consider when starting Parkinson’s disease treatment. Neurodegener Dis 2010;7(1-3):213-15
   PubMed Web of Science ®Google Scholar
• de la Fuente-Fernández R, Schulzer M, Mak E, Sossi V. Trials of neuroprotective therapies for Parkinson’s disease: problems and limitations. Parkinsonism Relat Disord 2010;16(6):365-9
   PubMed Web of Science ®Google Scholar
• Kupsch A, Sautter J, Gotz ME, et al. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline. J Neural Transm 2001;108(8-9):985-1009
   PubMed Web of Science ®Google Scholar
• Kronstrand R, Andersson MC, Ahlner J, Larson G. Incorporation of selegiline metabolites into hair after oral selegiline intake. J Anal Toxicol 2001;25(7):594-601
   PubMed Web of Science ®Google Scholar
• Kronstrand R, Ahlner J, Dizdar N, Larson G. Quantitative analysis of desmethylselegiline, methamphetamine, and amphetamine in hair and plasma from Parkinson patients on long-term selegiline medication. J Anal Toxicol 2003;27(3):135-41
   PubMed Web of Science ®Google Scholar
• Laine K, Anttila M, Huupponen R, et al. Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding. Clin Neuropharmacol 2000;23(1):22-7
   PubMed Web of Science ®Google Scholar
• Lecht S, Haroutiunian S, Hoffman A, Lazarovici P. Rasagiline - a novel MAO B inhibitor in Parkinson’s disease therapy. Ther Clin Risk Manag 2007;3(3):467-74
   PubMedGoogle Scholar
• Thorpy M. Therapeutic advances in narcolepsy. Sleep Med 2007;8(4):427-40
   PubMed Web of Science ®Google Scholar
• Hublin C, Partinen M, Heinonen EH, et al. Selegiline in the treatment of narcolepsy. Neurology 1994;44(11):2095-101
   PubMed Web of Science ®Google Scholar
• Roselaar SE, Langdon N, Lock CB, et al. Selegiline in narcolepsy. Sleep 1987;10(5):491-5
   PubMed Web of Science ®Google Scholar
• Thorpy MJ, Adler CH. Parkinson’s disease and sleep. Neurol Clin 2005;23(4):1187-208
   PubMed Web of Science ®Google Scholar
• Taylor DJ. Insomnia and depression. Sleep 2008;31(4):447-8
   PubMed Web of Science ®Google Scholar
• Rodnitzky RL, Narayanan NS. Amantadine’s role in the treatment of levodopa-induced dyskinesia. Neurology 2014;82(4):288-9
   PubMed Web of Science ®Google Scholar
• Lyytinen J, Kaakkola S, Ahtila S, et al. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson’s disease. Mov Disord 1997;12(4):497-505
   PubMed Web of Science ®Google Scholar
• Fox SH, Katzenschlager R, Lim SY, et al. The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson’s disease. Mov Disord 2011;26(Suppl 3):S2-41
   PubMed Web of Science ®Google Scholar
• Stern MB, Marek KL, Friedman J, et al. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson’s disease patients. Mov Disord 2004;19(8):916-23
   PubMed Web of Science ®Google Scholar